Biotech company Aldea has raised $24m in a series B round featuring WuXi PharmaTech and Rusnano, which will support the treatment of patients with acute alcohol intoxication.
Month: August 2014
Square seeks $200m in latest funding round
The mobile payment technology company has already raised $340m in equity funding from investors including Visa, Citi and Starbucks.
AirStrip plans foreign takeoff after $25m round
Mobile healthcare company Airstrip has raised $25m from investors including Qualcomm to expand into home health and foreign markets.
ViaCyte enters partnership with Janssen
Cell therapy company ViaCyte has entered into a rights agreement with Johnson & Johnson subsidiary Janssen following a $20m investment.
Median Technologies enters fundraising mode
The Canon-backed medical imaging company is set to raise $26m from a share issue to subscribers including IDInvest Partners.
China approves first national-level investment firm
The $8.1bn firm, China Minsheng Investment, is backed by 59 Chinese companies, none of which can own a stake greater than 2%.
Alibaba sets Super Class Table series B
Education app Super Class Table has raised an undisclosed amount of series B funding in a round led by Alibaba.
Tengelmann climbs aboard ClickBus for $10m series A
Rocket Internet start-up ClickBus, founded last year, has received $10m in series A funding in a round featuring retail group Tengelmann.
Civitas to collect up to $86m in IPO
The Parkinson’s disease drug developer has filed for an initial public offering the day after closing a $55m Alkermes-backed series C round.
Dell reaches Lastline for $10m series C
Computer security company Lastline has raised $10m in a series B round featuring Dell Ventures, bringing the total funding raised by the company to close to $21m.
HubSpot targets $100m from IPO
The Google and Salesforce-backed sales and marketing software company has raised about $100m in venture funding so far.
Zumigo locates $6m for series B
Mobile device and location verification service Zumigo has raised $6m in series B round from Intel Capital and Aligned Partners.
Johnson & Johnson buys Novartis-backed Covagen
Covagen, which is developing treatments for cancer and inflammatory diseases, has been acquired for an undisclosed sum, granting exits to Novartis and Seroba Kernel.
Taulia’s growth soars more than 350%
Telus-backed Taulia has increased its year-on-year revenue 350% in the second quarter of 2014.